These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
306 related items for PubMed ID: 17603267
21. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Zhao W, Fakhoury M, Jacqz-Aigrain E. Ther Drug Monit; 2010 Dec; 32(6):688-99. PubMed ID: 21068645 [Abstract] [Full Text] [Related]
22. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK. Transplantation; 2009 Apr 27; 87(8):1225-31. PubMed ID: 19384171 [Abstract] [Full Text] [Related]
23. A transient increase of calcineurin phosphatase activity in living-donor kidney transplant recipients with acute rejection. Fukudo M, Yano I, Katsura T, Ito N, Yamamoto S, Kamoto T, Ogawa O, Inui K. Drug Metab Pharmacokinet; 2010 Apr 27; 25(5):411-7. PubMed ID: 20834189 [Abstract] [Full Text] [Related]
24. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Masuda S, Uemoto S, Goto M, Fujimoto Y, Tanaka K, Inui K. Clin Pharmacol Ther; 2004 Apr 27; 75(4):352-61. PubMed ID: 15060513 [Abstract] [Full Text] [Related]
25. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients. Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L. Gene; 2013 Jan 10; 512(2):226-31. PubMed ID: 23107770 [Abstract] [Full Text] [Related]
27. Unusual high dose of tacrolimus in liver transplant patient, a case report. Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, D'Antoni A, Polidori P, Vizzini G, D'Alessandro N. Int J Clin Pharm; 2012 Apr 10; 34(2):269-71. PubMed ID: 22422348 [Abstract] [Full Text] [Related]
28. [Effect of genetic polymorphism of cytochrome P450 3A and transporter gene on pharmacokinetics of tacrolimus, a calcineurin inhibitor]. Niwa T, Shiraga T, Omura M, Kondo T, Kuroda M, Takagi A. Nihon Yakurigaku Zasshi; 2006 Dec 10; 128(6):395-404. PubMed ID: 17167213 [No Abstract] [Full Text] [Related]
29. Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients. Tron C, Woillard JB, Houssel-Debry P, David V, Jezequel C, Rayar M, Balakirouchenane D, Blanchet B, Debord J, Petitcollin A, Roussel M, Verdier MC, Bellissant E, Lemaitre F. PLoS One; 2020 Dec 10; 15(3):e0230195. PubMed ID: 32163483 [Abstract] [Full Text] [Related]
30. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, Tassaneeyakul W. Clin Ther; 2013 Nov 10; 35(11):1762-9. PubMed ID: 24120259 [Abstract] [Full Text] [Related]
32. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients. Andrews LM, Li Y, De Winter BCM, Shi YY, Baan CC, Van Gelder T, Hesselink DA. Expert Opin Drug Metab Toxicol; 2017 Dec 10; 13(12):1225-1236. PubMed ID: 29084469 [Abstract] [Full Text] [Related]
33. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R. Exp Clin Transplant; 2015 Apr 10; 13 Suppl 1():197-200. PubMed ID: 25894154 [Abstract] [Full Text] [Related]
34. "What do we know about tacrolimus pharmacogenetics in transplant recipients?". Kuypers DR. Pharmacogenomics; 2018 May 10; 19(7):593-597. PubMed ID: 29701126 [No Abstract] [Full Text] [Related]
35. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Jordán de Luna C, Herrero Cervera MJ, Sánchez Lázaro I, Almenar Bonet L, Poveda Andrés JL, Aliño Pellicer SF. Transplant Proc; 2011 May 10; 43(6):2241-3. PubMed ID: 21839244 [Abstract] [Full Text] [Related]
36. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K. Pharmacogenet Genomics; 2008 May 10; 18(5):413-23. PubMed ID: 18408564 [Abstract] [Full Text] [Related]
37. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction]. Cofán F, Gutiérrez R, Beardo P, Campistol JM, Oppenheimer F, Alcover J. Nefrologia; 2002 May 10; 22(5):470-6. PubMed ID: 12497749 [Abstract] [Full Text] [Related]
38. Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs. Lytton SD, Berg U, Nemeth A, Ingelman-Sundberg M. Clin Exp Immunol; 2002 Feb 10; 127(2):293-302. PubMed ID: 11876753 [Abstract] [Full Text] [Related]
39. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. Clin Pharmacol Ther; 2007 Dec 10; 82(6):711-25. PubMed ID: 17495880 [Abstract] [Full Text] [Related]
40. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period? Singh R, Srivastava A, Kapoor R, Mittal RD. J Clin Pharmacol; 2011 Apr 10; 51(4):603-15. PubMed ID: 20571034 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]